Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	220.97B
Revenue (ttm)	14.45B
Net Income (ttm)	5.24B
Shares Out	6.05B
EPS (ttm)	0.88
PE Ratio	41.48
Forward PE	38.18
Dividend	0.37 (1.01%)
Ex-Dividend Date	Sep 22, 2025

Volume	10,424,133
Average Volume	7,528,391
Open	37.14
Previous Close	35.74
Day's Range	36.04 - 37.58
52-Week Range	15.96 - 39.76
Beta	0.61
RSI	50.76
Earnings Date	Nov 18, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY